Navigation Links
New study finds that add-on therapy improves depressive symptoms in bipolar disorder
Date:9/2/2008

Philadelphia, PA, September 2, 2008 Lingering depression is a serious and common problem in bipolar disorder, and does not resolve well with existing treatments. Because individuals with both depression and bipolar disorder experience a glutathione deficiency, an antioxidant that protects cells from toxins, researchers in a new study scheduled for publication in the September 15th issue of Biological Psychiatry sought to evaluate whether N-acetyl cysteine (NAC), an over-the-counter supplement that increases brain glutathione, might help alleviate depressive symptoms.

Dr. Michael Berk and colleagues, in a randomized, double-blind, placebo-controlled trial, evaluated the mood symptoms of individuals with bipolar disorder, half of whom received placebo and half of whom received NAC, as an add-on therapy to their usual treatment. Over the 24 weeks of the study, NAC was well tolerated, and induced a marked and significant improvement in depressive symptoms. Ashley Bush, M.D., Ph.D., the article's corresponding author, further explains: "Glutathione is the brain's primary antioxidant defense, and there is evidence of increased oxidative stress in bipolar disorder. Therefore, we studied the potential benefit of NAC treatment in bipolar disorder and found that it impressively remedied residual depressive symptoms."

John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, comments: "The preliminary evidence of efficacy of NAC is very interesting. This study might suggest a number of novel approaches to treating depression. In subsequent efforts to replicate this preliminary finding, it will be important to determine how much NAC reaches the brain after oral administration." As noted by both the authors and Dr. Krystal, additional studies will be necessary to further evaluate and replicate these findings. However, as Dr. Berk observes, "Br
'/>"/>

Contact: Jayne Dawkins
ja.dawkins@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

1

GOOD

Page: 1 2

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Dec. 14 Abbott (NYSE: ... agreement to acquire STARLIMS Technologies Ltd. (Nasdaq: ... laboratory information management systems, for approximately $123 ... strengthens Abbott,s competitive position in the global ... help laboratories efficiently store, retrieve and analyze ...
(Date:12/14/2009)... Ga., Dec. 14 Aflac Incorporated announced ... value) of thirty-year senior notes with a coupon ... a price of 98.951 to yield 6.984%. The ... for debt repayment and general corporate purposes. ,, ... Aflac Incorporated President and Chief Financial Officer Kriss ...
(Date:12/14/2009)... gene, researchers say , , MONDAY, Dec. 14 (HealthDay News) ... in a single gene linked to heart failure. , ... St. Louis analyzed the DNA of a large group ... variants in four genes that could be connected with ... failure and 625 healthy whites led the researchers to ...
(Date:12/14/2009)... higher than generally thought, raising concerns about increased risk for cancer, ... San Francisco (UCSF) imaging specialists. , ... San ... CT procedures vary widely and are higher than generally thought, raising ... led by University of California, San Francisco (UCSF) imaging ...
(Date:12/14/2009)... Calif., Dec. 14 Grubb & Ellis Healthcare REIT ... authorized a daily distribution to stockholders of record as of ... commencing on Jan. 1, 2010 and ending on Feb. 28, ... days in the calendar year and will be equal to ... price of $10.00 per share. These distributions will be ...
Breaking Medicine News(10 mins):Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 2Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 3Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 4Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 2Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 3Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 4Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 2Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 3Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 4Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 5Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 2Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 3
... unchanged since 1970s, despite higher spending on care, study shows ... cost more than $1 million to give a lung cancer ... disease hasn,t increased significantly, a new study finds. , On ... than one month between 1983 and 1997. At the same ...
... Additional Key Gene Locus as a ... Recently-Funded Company, NEW HAVEN, Conn., Oct. 23 ... dry and wet Age-related Macular,Degeneration (AMD) and other chronic ... has licensed from the University,of Pittsburgh the worldwide rights ...
... MINNEAPOLIS, Oct. 23 Less than one month ... than 3,000 scientists and,health advocates are converging on ... or Health (NCTOH) conference October 24-26,at the Minneapolis ... and longest-lasting gathering of the U.S.,tobacco control movement. ...
... Inc., a leading,provider of software and databases for ... MetaCore Data Mining Suite to AVEO,Pharmaceuticals. The latest ... functional ontology. MetaCore has an in depth,knowledge base ... concurrently,visualize gene expression, proteomics, genetic and metabolic data. ...
... for School Absenteeism, Hair Fairies Salon Success ... Detangling Problem One US City at a Time, LOS ANGELES, ... the nation,s most challenged, will have the opportunity to,save $2.5 million, ... According to entrepreneur Maria Botham, lice,infestation is the #1 reason for ...
... forum designed to connect healthcare communities throughout ... ... During the World of,Health IT Conference and Exhibition today in ... announced,a broad expansion of the Microsoft Healthcare Users Group (MS-HUG) to,partners ...
Other Medicine News:Health News:More Dollars Don't Boost Lung Cancer Survival 2Health News:More Dollars Don't Boost Lung Cancer Survival 3Health News:Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations 2Health News:Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations 3Health News:Minneapolis Hosts National Conference on Tobacco or Health October 24-26 on Heels of Minnesota's Statewide, Smoke-Free Law 2Health News:GeneGo Licenses MetaCore Data Analysis Suite to AVEO Pharmaceuticals 2Health News:Gold Standard for Lice Removal Opens in Lincoln Park to Save School System $2.5 million 2Health News:Microsoft and HIMSS Expanding Healthcare User Group Across EMEA 2Health News:Microsoft and HIMSS Expanding Healthcare User Group Across EMEA 3Health News:Microsoft and HIMSS Expanding Healthcare User Group Across EMEA 4
(Date:12/14/2009)... THE WOODLANDS, Texas, Dec. 14 /PRNewswire/ ... investigators affiliated with US Oncology ... were presented orally at the ... , held Dec. 9-13 at the ... in San Antonio, Texas . ...
(Date:12/14/2009)... Cardinal Health today announced that executives of ... ,, Goldman Sachs CEO Unplugged Conference ... Sachs Conference Center in New York. 28th ... at Noon EST at the Westin St. Francis Hotel ... executives will discuss Cardinal Health,s diverse products and services, ...
(Date:12/14/2009)... Southridge LLC ("Southridge"), an investment firm that provides ... announce that its affiliated fund has closed a private ... equity financing to Imaging Diagnostic Systems, Inc. (OTCBB: IMDS). ... growth of Imaging Diagnostic Systems, Southridge has paved a ... the field of early breast cancer detection," said Stephen ...
Breaking Medicine Technology:US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 2US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 3US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 4US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 5US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 6US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 7US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 8US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 9Cardinal Health Executives to Speak at Two Investor Events in January 2Southridge LLC Provides Funding Through Private Equity Agreement with Imaging Diagnostic Systems, Inc. 2Meda Introduces EDLUAR 28TM 29 the First and Only Sublingual Tablet That Contains the Most Prescribed Sleep Medication Zolpidem Tartrate 56404 1Meda Introduces EDLUAR 28TM 29 the First and Only Sublingual Tablet That Contains the Most Prescribed Sleep Medication Zolpidem Tartrate 56404 2Meda Introduces EDLUAR 28TM 29 the First and Only Sublingual Tablet That Contains the Most Prescribed Sleep Medication Zolpidem Tartrate 56404 3Meda Introduces EDLUAR 28TM 29 the First and Only Sublingual Tablet That Contains the Most Prescribed Sleep Medication Zolpidem Tartrate 56404 4Delta Health an InfoLogix Company Wins Engagement with Hennepin County Medical Center for Strategic Cost Management 56400 1Delta Health an InfoLogix Company Wins Engagement with Hennepin County Medical Center for Strategic Cost Management 56400 2Delta Health an InfoLogix Company Wins Engagement with Hennepin County Medical Center for Strategic Cost Management 56400 3Genova files patent for new prostate cancer treatment 56395 1Genova files patent for new prostate cancer treatment 56395 2
... at AASLD annual meeting, Pivotal Phase III ... failed prior treatment, SAN FRANCISCO, Nov. 1 ... that a planned interim analysis of a,Phase II ... C,protease inhibitor, in combination with peginterferon and ribavirin,markedly ...
... I Clinical Data and Additional Preclinical Results for Non-Nucleoside ... Polymerase Inhibitor Being Presented at AASLD, SAN DIEGO, Nov. ... the results of a Phase I clinical trial,of ANA598 in ... of the leading non-nucleoside polymerase inhibitors,currently in development for the ...
Other Medicine Technology:Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 2Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 3Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 4Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 5Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 6Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 7Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 8Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 9Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 10Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers 2Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers 3Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers 4Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers 5Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers 6
The dryer is designed to rapidly dry slides by blowing warm air over the surface of the slides. The slide dryer accommodates two slide racks directly from a stainer and allows the slides to be staine...
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
... have a positive and negative inoculated well, ... these slides, perform QC and sample staining ... education and training programs by testing QC ... on one slide! KWIK-QC slides contain the ...
... Well Plate Capability The Equalizer 384 ... Equalizerexpandable and equal tip spacing, choice of two ... In addition, this model allows you to evenly ... and accessing many gels and for use with ...
Medicine Products: